Clinical Trials Directory

Trials / Completed

CompletedNCT03965793

Individualized Fluid And Vasopressor Administration In Surgical Patients

Individualized Fluid and Vasopressor Administration in Surgical Patients: A Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
38 (actual)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare two different strategies of intraoperative mean arterial pressure (MAP) and stroke volume index management in high-risk patients undergoing major abdominal and orthopedic surgery (manual versus automated) The investigators hypothesis is that the automated group will spend less time during surgery in hypotension (defined as a MAP\<90% of patient's MAP baseline) compared to the manual group.

Detailed description

The maintenance of MAP is essential for organ perfusion pressure. Intraoperative hypotension is a frequent complication both after induction and during maintenance of anaesthesia, ranging from 5% to 75% depending on the chosen definition. Tissue hypoperfusion exposes to the occurrence of a systemic inflammatory response syndrome and is a key determinant of postoperative complications. Persistent intraoperative hypotension has been reported as an important prognostic factor of postoperative morbidity and mortality. Adequate treatment of arterial hypotension is therefore of particular importance during surgery. However, the avoidance of hypotension includes the infusion of vasopressor and/or fluid to optimize perfusion pressure. The manual adjustment of vasopressor administration has been shown to be suboptimal. Recently, a paper published in the JAMA journal demonstrated that among patients undergoing high-risk surgery, the maintenance of blood pressure within 10% of patient's baseline systolic blood pressure resulted in less postoperative organ dysfunction compared to standard MAP management. Today, the investigators have an automated clinical decision support system that help ease the administration of both fluid and vasopressors during surgery (individualized fluid and vasopressor administration). The department of the investigators has recently implemented a manual hemodynamic protocol to optimize fluid and vasopressor. The goal is to maintain stroke volume index within 90% of the optimal stroke volume via mini fluid challenge of crystalloid solution (100 ml) following the French guidelines and to maintain MAP within 90 % of patient's baseline MAP. This protocol has been called : Individualized Fluid and vasopressor protocol (because based on patient's values) The purpose of this study is therefore to compare two different strategies of intraoperative mean arterial pressure (MAP) and stroke volume index management in high-risk surgical patients (manual versus automated and decision support guided) The investigators hypothesis is that automated group will spend less time during surgery in hypotension (defined as a MAP\<90% of patient's MAP baseline) compared to the manual group because patient's stroke volume and MAP will be better maintained during surgery (within 10% of patient' targets).The decision support system will remind the clinician when to administer a bolus of fluid to maintain stroke volume index within 10% of the optimize stroke volume index value and an automated closed-lopp system will titrate norepinephrine to keep MAP within 10% of patient's MAP target. The study will thus compare an individualized hemodynamic protocol (already in place in our institution) applied manually to a decision support-and closed-loop guided- individualized hemodynamic protocol (intervention group).

Conditions

Interventions

TypeNameDescription
DEVICEAutomated management of hypotensionFluid and vasopressor will be administered based on a novel automated clinical decision support system.

Timeline

Start date
2019-10-27
Primary completion
2020-07-26
Completion
2020-07-26
First posted
2019-05-29
Last updated
2021-03-02

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03965793. Inclusion in this directory is not an endorsement.